Koers Reshape Lifesciences Inc Nasdaq
Aandelen
US7611234052
Geavanceerde medische apparatuur & technologie
Omzet 2024 * | 9,99 mln. 9,2 mln. | Omzet 2025 * | 11,99 mln. 11,04 mln. | Marktkapitalisatie | 4,95 mln. 4,55 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -6 mln. -5,52 mln. | Nettowinst (verlies) 2025 * | -5 mln. -4,6 mln. | EV/omzet 2024 * | 0,49 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,41 x |
K/w-verhouding 2024 * |
-0,47
x | K/w-verhouding 2025 * |
-0,59
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 88,83% |
Recentste transcriptie over Reshape Lifesciences Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paul Hickey
CEO | Chief Executive Officer | 59 | 01-02-20 |
Director of Finance/CFO | 63 | 15-06-21 | |
Dov Gal
CMP | Compliance Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gary Blackford
BRD | Director/Board Member | 66 | 01-01-16 |
Dan Gladney
CHM | Chairman | 70 | 01-11-15 |
Director/Board Member | 70 | 15-06-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+11,91% | 227 mld. | |
+15,46% | 197 mld. | |
+18,58% | 141 mld. | |
+30,36% | 110 mld. | |
+0,65% | 64,15 mld. | |
+17,74% | 53,72 mld. | |
+5,82% | 51,75 mld. | |
+11,23% | 45,2 mld. | |
+5,73% | 37,37 mld. |